SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Should You Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) gapped down prior to trading on Thursday . The stock had previously closed at $11.66, but opened at $11.31. SELLAS Life Sciences Group shares last traded at $11.4120, with a volume of 916,056 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SLS shares. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Trading Down 2.0%

The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -54.53 and a beta of 2.52. The firm has a 50-day moving average of $12.58 and a two-hundred day moving average of $8.94.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC bought a new position in SELLAS Life Sciences Group during the fourth quarter worth about $26,000. Nykredit A S bought a new stake in SELLAS Life Sciences Group during the 2nd quarter worth approximately $27,000. California State Teachers Retirement System raised its holdings in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares during the period. Wealthfront Advisers LLC bought a new position in SELLAS Life Sciences Group in the first quarter valued at approximately $48,000. Finally, Principal Financial Group Inc. bought a new position in SELLAS Life Sciences Group in the first quarter valued at approximately $53,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The company’s research programs are aimed at treating hematologic malignancies and solid tumors through immunotherapy and targeted drug development.

SELLAS’s lead immunotherapy candidate is galinpepimut-S, or GPS, an investigational peptide vaccine designed to stimulate an immune response against Wilms’ tumor 1 (WT1), a protein associated with several cancers.